Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Genentech, a member of the Roche Holdings AG (OTC:RHHBY), announced new Ocrevus (ocrelizumab) data shows a benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS0 and secondary progressive MS (SPMS).
- The company noted that 75% of patients achieved no evidence of progression (NEP) in a one-year interim analysis of the CONSONANCE study.
- 70% of patients demonstrated stable or improved cognition after one year of Ocrevus treatment.
- A separate analysis of treatment disparities showed that fewer Black and Hispanic patients with MS initiate high-efficacy treatments within two years of diagnosis.
- Ocrevus is approved in 100 countries across North America, South America, the Middle East, Eastern Europe, Australia, Switzerland, the United Kingdom, and the EU.
- Multiple sclerosis occurs when the immune system abnormally attacks the insulation and support around nerve cells (myelin sheath) in the central nervous system (brain, spinal cord, and optic nerves).
- After one year, 75% of patients had one or more adverse events (AEs), and 7% experienced at least one serious AE.
- The interim analysis included 629 patients, and the longer-term evaluation of OCREVUS will continue for four years with a target of 900 patients.
- Price Action: RHHBY shares are up 1.35% at $51.17 during the market session on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!